Harvard | Ms. Ambitious Hippie
GRE 329, GPA 3.9
Stanford GSB | Mr. Classic Candidate
GMAT 760, GPA 3.9
Harvard | Ms. Athlete Entrepreneur
GMAT 750, GPA 3.3
Stanford GSB | Mr. Unrealistic Ambitions
GMAT 710, GPA 2.0
Stanford GSB | Mr. Equal Opportunity
GMAT 760, GPA 4.0
Tuck | Mr. Over-Experienced
GRE 330, GPA 3.0
HEC Paris | Mr. Indian Entrepreneur
GMAT 690, GPA 2.1
Chicago Booth | Mr. Community Uplift
GMAT 780, GPA 2.6
UCLA Anderson | Mr. Worldwide
GMAT 730, GPA 3.1
Darden | Mr. Education Consulting
GRE 326, GPA 3.58
Wharton | Mr. LatAm Indian Trader
GMAT 720, GPA 3.5
Wharton | Mr. MBB to PE
GMAT 740, GPA 3.98
Darden | Mr. Stock Up
GMAT 700, GPA 3.3
Harvard | Mr. MBB Aspirant
GMAT 780, GPA 3.7
Harvard | Ms. Finance
GMAT 760, GPA 3.48
Harvard | Mr. Soldier Boy
GMAT 720, GPA 3.72
Cornell Johnson | Mr. Angel Investor
GMAT 700, GPA 3.20
Rice Jones | Mr. ToastMasters Treasurer
GMAT 730, GPA 3.7
Kellogg | Mr. MBB Private Equity
GMAT TBD (target 720+), GPA 4.0
Said Business School | Ms. Creative Planner
GMAT 690, GPA 3.81 / 5.0
Stanford GSB | Mr. Wedding Music Business
GMAT 710, GPA 3.7
Harvard | Mr. Big 4 Auditor
GMAT 740, GPA 3.55
Harvard | Mr. Software PE
GMAT 760, GPA 3.45
Harvard | Mr. First Gen Consultant
GMAT 710, GPA 4.0 (First Class Honours)
Stanford GSB | Mr. MBB/FinTech
GMAT 760, GPA 3.7
Stanford GSB | Mr. Break Into Buy-Side
GMAT 780, GPA 3.6
Harvard | Mr. Perseverance
GMAT 730, GPA 3.7

NFL Owner Kraft Gives HBS $20 Million

NFL Owner Robert Kraft

NFL Owner Robert Kraft

As Harvard Business School MBA and corporate titan Robert Kraft’s wife lay dying of cancer, Kraft frequently consulted with former HBS professor Eric Lander, founding director of the biomed-focused Harvard/MIT Broad Institute. Myra Kraft passed away in 2011, but the relationship that grew between her husband and Lander has now led to a major gift to HBS, an endowment intended to deliver a boost to a cutting-edge field of medicine – and bring new opportunities for MBAs.

The school announced today (Nov. 18) a $20 million endowment to HBS from the Robert and Myra Kraft Foundation, to create the Kraft Endowment for Advancing Precision Medicine. Precision medicine, also called “personalized medicine,” combines a patient’s genetic, lifestyle, and environment information to enable targeted, individualized medical treatment.

“For all diseases this is the new approach that virtually all big pharma and certainly startup R&D efforts are going after – targeted therapies, not large broad-based therapies,” says HBS management professor Richard Hamermesh. “Most drugs work for no more than 60% of the people that take them. Diseases and humans all different. It’s not like one size serves all.”

Harvard Business School - Ethan Baron photo

Harvard Business School – Ethan Baron photo


The donation pledge brings Harvard closer to the goal of a capital campaign announced last year to bring in $1 billion over five years. By the end of this past June, HBS had raised $861 million, with $261 million of that brought in after the official April 2014 announcement.

Billionaire donor Kraft, who received his HBS MBA in 1965 and owns the New England Patriots, wants to see results from his donation as quickly as possible, Hamermesh says. “He doesn’t want more people suffering the same fate that his wife did,” Hamermesh adds.

Precision medicine is used extensively in cancer treatment. “In most cases, tumors are (genetically) sequenced so you understand exactly what the genetic mutations are in a particular cancer, and then you treat the mutations,” Hamermesh says. “In time, cancers will be known not so much as lung cancer or liver cancer or whatever, but they’ll be known by the mutations in the genetic pathways that are being disrupted.”

Genetics-based precision treatment is also used for cystic fibrosis, which is caused by irregularities in a single gene. Precision medicine identified three different mutations, and there are treatments for two of them, meaning that about 65% of U.S. children diagnosed with the disease will be treated as long as they live, but never develop symptoms, Hamermesh says. AIDS, too, is addressed with precision medicine – the virus is sequenced to identify mutations, and drug cocktails prescribed based on which mutations are present.


Barriers to expansion of precision medicine are 70% business problems and only 30% science problems, Hamermesh says. “You need lots of data that organizations and institutions need to share to do the numerical analysis linking aberrations and mutations in genes to specific diseases,” he says. “That’s where the B-school comes in.